SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020
5 references·0 citing·11 second hop
Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020 (2022)Overall Survival Benefits of Cancer Drugs…Updating Reports of Phase 3 Clinical Trials for Cancer (2021)Updating Reports of Phase 3 C…Characteristics of expedited programmes for cancer drug approval in China (2021)Characteristics of expedited …FDA Approval and Regulation of Pharmaceuticals, 1983-2018 (2020)FDA Approval and Regulation o…The changing landscape of clinical trial and approval processes in China (2017)The changing landscape of cli…Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13 (2017)Availability of evidence of b…A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) (2015)Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets (2018)Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval (2019)Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis (2019)Are published manuscripts representative of the surgical meeting abstracts? An objective appraisal (1987)AN OBSERVATIONAL STUDY OF ORTHOPAEDIC ABSTRACTS AND SUBSEQUENT FULL-TEXT PUBLICATIONS (2002)Transition From Meeting Abstract to Full-length Journal Article for Randomized Controlled Trials (2006)Evolution of drug regulations and regulatory innovation for anticancer drugs in China (2022)A Decade of FDA-Approved Drugs (2010–2019): Trends and Future Directions (2021)How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment (2021)Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy (2023)
this work references cited by second hop

References

  • 2017Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13600 cited
  • 2020FDA Approval and Regulation of Pharmaceuticals, 1983-2018377 cited
  • 2017The changing landscape of clinical trial and approval processes in China68 cited
  • 2021Characteristics of expedited programmes for cancer drug approval in China53 cited
  • 2021Updating Reports of Phase 3 Clinical Trials for Cancer8 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work